Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2002-10-30
2008-11-25
Desai, Rita J (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S301000, C514S302000, C514S304000, C544S350000, C546S114000, C546S115000
Reexamination Certificate
active
07456192
ABSTRACT:
The invention concerns compounds of general formula 1, wherein: A, B, D and E represent one or two nitrogen atoms, the others being carbon atoms; X represents a S or, a O, thereby forming a bicyclic fused heteroaromatic, such as thieno[2,3-b]pyridine, furo[2,3-b]pyridine, thieno[3,2-b]pyridine, furo[3,2-b]pyridine, thieno[2,3-b]pyrazine, furo[2,3-b]pyrazine, thieno[2,3-c]pyridine, furo[2,3-c]pyridine, thieno[3,2-c]pyridine and furo[3,2-c]pyridine; R1 represents a linear or branched C1-C6alkoxy group, a linear or branched C1-C6alkylthio group; R2 represents a linear, branched, cyclic C2-C8group, a 2- or 3-thienylmethyl group, or a benzyl group optionally substituted by one or several halogens, F, Cl, Br, I, C1-C4alkyl, C1-C4alkoxy, CF3, CN, NO2, OH; and their pharmaceutically acceptable salts. Said compounds are anti-dopaminergic agents.
REFERENCES:
patent: 4536580 (1985-08-01), Dostert et al.
patent: 4910193 (1990-03-01), Buchheit
patent: 0013138 (1979-12-01), None
patent: WO 93/15052 (1993-08-01), None
patent: WO 97/10244 (1997-03-01), None
patent: WO 01/14333 (2001-03-01), None
Dorwald F. A. Side Reactions in Organic Synthesis, 2005, Wiley: VCH, Weinheim p. IX of Preface.
“Antipsychotic Drugs, Neurotransmitters, and Schizophrenia” Carlsson A., Am.J. Psychiatry, 135, 164-173, 1978.
“New drugs for the treatment of schizophrenic patients” Acta Psychiatr. Scand., 1995, 91 (Suppl 388): 24-30.
Dopamine D2 receptors selectively labeled by a benazmide neuroleptic . . . : H.B. Niznik et al, Naunyn-Schmiedeberg's Arch. Pharmacol. 329-333-343, 1985.
“Inhibition of Methylphenidate-Induced Behaviors in Rats: Differences Among Neuropleptics”, W. Koek, F.C. Colpaert, J. Pharmacol. Exp. Ther. 267, 181-191, 1993.
“Tropapride hydrochloride”, Drugs of the Future, vol. 9, No. 9, 673-674, 1984.
“The cataleptogenic effects of the neuroleptic nemonapride are attenuated by its 5-HT receptor agonist properties”, e. Prinssen et al, Eur. J. Pharmacol. 356, 189-192, 1998.
“Studies on the neuroleptic benzamides III-Synthesis and antidopaminergic properties of new 3-nortropane deriatives”, Sostert et al, Eur. J. Med. Chem. 1984, 19, 105-110.
M.N. Romanelli, et al. “Synthesis and Biological Activity of a Series of Aryl Tropanyl Esters and Amides Chemically Related to 1H-Indole-3-carboxylic Acid endo 8-Methyl-8-azabicyclo[3.2.1]oct-3-yl Ester”, Arzneim.-Forsch. (1993), pp. 913-918.
Imbert Thierry
Koek Wouter
Monse Barbara
Birch & Stewart Kolasch & Birch, LLP
Desai Rita J
Pierre Fabre Medicament
LandOfFree
3β-amino azabicyclooctane heteroaromatic amid... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 3β-amino azabicyclooctane heteroaromatic amid..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 3β-amino azabicyclooctane heteroaromatic amid... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4031345